Vermillion Wealth Management, Inc. Cytokinetics Inc Transaction History
Vermillion Wealth Management, Inc.
- $370 Billion
- Q3 2025
A detailed history of Vermillion Wealth Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Vermillion Wealth Management, Inc. holds 10 shares of CYTK stock, worth $593. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10Holding current value
$593% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
383Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.04 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$871 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$711 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$465 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$378 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.59B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...